Skip to main content
Erschienen in: BMC Health Services Research 1/2023

Open Access 01.12.2023 | Research

Development and evaluation of a customized checklist to assess the quality control of disease registry systems of Tehran, the capital of Iran in 2021

verfasst von: Maryam Barzin, Hamideh Sabbaghi, Sharareh Kamfar, Atena Seifi, Mahmoud Hajipour, Fatemeh Hadavand Siri, Elham Mir-Moeini, Anis Gharajeh, Nasrin Ferdosifard, Mohammadhossein Panahi, Seyed Saeed Hashemi Nazari, Fatemeh Fallah Atatalab, Koorosh Etemad

Erschienen in: BMC Health Services Research | Ausgabe 1/2023

Abstract

Background

Clinical registries facilitate medical research by providing ‘real data’. In the past decade, an increasing number of disease registry systems (DRS) have been initiated in Iran. Here, we assessed the quality control (QC) of the data recorded in the DRS established by Shahid Beheshti University of Medical Sciences in Tehran, the capital city of Iran, in 2021.

Methods

The present study was conducted in two consecutive qualitative and quantitative phases and employed a mixed-method design. A checklist containing 23 questions was developed based on a consensus reached following several panel group discussions, whose face content and construct validities were confirmed. Cronbach’s alpha was calculated to verify the tool’s internal consistency. Overall, the QC of 49 DRS was assessed in six dimensions, including completeness, timeliness, accessibility, validity, comparability, and interpretability. The seventy percent of the mean score was considered a cut-point for desirable domains.

Results

The total content validity index (CVI) was obtained as 0.79, which is a reasonable level. Cronbach’s alpha coefficients obtained showed acceptable internal consistency for all of the six QC domains. The data recorded in the registries included different aspects of diagnosis/treatment (81.6%) and treatment quality requirements outcomes (12.2%). According to the acceptable quality cut-point, out of 49 evaluated registries, 48(98%), 46(94%), 41(84%), and 38(77.5%), fulfilled desirable quality scores in terms of interpretability, accessibility, completeness, and comparability, however, 36(73.5%) and 32(65.3%) of registries obtained the quality requirement for timeliness and validity, respectively.

Conclusion

The checklist developed here, containing customized questions to assess six QC domains of DRSs, provided a valid and reliable tool that could be considered as a proof-of-concept for future investigations. The clinical data available in the studied DRSs fulfilled desirable levels in terms of interpretability, accessibility, comparability, and completeness; however, timeliness and validity of these registries needed to be improved.
Hinweise
Maryam Barzin and Hamideh Sabbaghi contributed equally to this work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Clinical registries are interactive real-time databases recording the detailed information of patients, including specific diagnoses, clinical conditions, and procedures [1]. A clinical registry is typically customized to fulfill its major purposes, including describing the natural history of diseases, treatments, medications, and their clinical efficacy and cost-effectiveness, as well as disease outcomes and safety and quality of care issues [2, 3]. In 1974, the World Health Organization (WHO) pioneered these registries in epidemiological and clinical research [4], and since then disease registry systems (DRSs) have turned into organized systems to improve the quality of care in the healthcare system and progress in medical research [5, 6]. Disease registry systems provide opportunities to conduct high-quality medical research, advance diagnostic and therapeutic clinical practice guidelines, and improve the quality of healthcare services, patient outcomes, and resource and financial management. In addition, DRSs can show us the best way to strategic purchasing and conduct cohort and clinical trials based on real data [7, 8], especially for rare diseases [9].
However, using databases for research and audit and answering specific questions require high-quality data and resolving the weaknesses of DRSs [10]. Quality control (QC), as an integrated system, is an important component of the quality management of data registries, helping in dynamic monitoring and evaluating the effectiveness of the construct and process of data registration according to predetermined goals. As with any project, DRSs should be evaluated by a supervisor appointed by the founder. This process helps DRSs improve themselves and correct their errors, such as missing data, delayed follow-up, and data duplication [4, 11, 12]. Therefore, clinical DRSs need to be validated and improved as their quality assessment results are provided to policymakers and health insurance companies and are used for making public-heath related decisions.
In Iran, DRSs started to grow 30 years ago when the cancer registry and then other national registries such as trauma, spinal defects, and newborn anomalies were established [1316]. In 2014, a national DRS program was created aiming to integrate at least 20 DRSs in Iran. Until November 2018, a total of 71 clinical DRSs were active in the medical universities and health institutions affiliated with Iran’s Ministry of Health and Medical Education, among which Shahid Beheshti University of Medical Sciences (SBMU), with six DRSs, ranked fifth until then. This university now hosts around 50 DRSs for different medical specialties. The pillar of dynamic monitoring of these DRSs is to validate their different QC dimensions and integrate them into a meaningful whole to provide comprehensive coverage while keeping these dimensions organized and integrating them with the health information system (HIS).
Because it is inapplicable to interpolate all internationally used QC dimensions into all DRSs, we here developed a checklist to monitor the most important QC dimensions including comparability [17], reliability, and validity [18], completeness [19], timeliness [11], accessibility [20], efficiency, and duplication [2]. The second purpose was to evaluate the quality of 49 DRSs.

Methods

The present study had a mixed-method design and was conducted in two consecutive qualitative and quantitative phases. In the qualitative phase, a checklist was developed to assess the QC of 49 active DRSs established by the research centers, hospitals, and educational departments affiliated with the Shahid Beheshti University of Medical Sciences (SBMU). In these DRSs, the data were launched using unique and standard software, and crude data were transferred from actively supervised registries approved by SBMU. Registries with no recorded data were excluded.

Ethical consideration

This study’s procedures were approved by the Ethics Committee of SBMU under the registration number IR.SBMU.RETECH.REC.1400.577.

Qualitative phase: checklist development

A working group consisting of 13 experts was formed to develop a checklist through a panel group discussion and brainstorming. The working group’s members included epidemiologists (n = 3), medical informatics specialists (n = 3), social medicine specialists (n = 3), health policymakers with experience in the field of DRSs (n = 2), and two DRS professionals. First, an initial form of the checklist was designed based on the standards released by the Ministry of Health of Iran, and then it was further updated based on the key points extracted from relevant articles retrieved by systematically searching different databases. Finally, a checklist with 29 items was developed, and each item was scored on a five-point Likert scale from "not important" (one score) to "very important" (five scores). A total of three panel-group discussion sessions were held with the participation of all 13 experts. During the first session, questions with scores of 4 or 5 were kept and further examined in the subsequent panel-group sessions, and questions obtaining a score of < 4 were omitted. At the end of the third panel-group discussion, a checklist with 23 items was finalized.
The questions were developed in a way to evaluate different QC aspects of the registries, including structure management, data sources, data elements, registry software, recording processes, registry outcomes, user training, and the performance of the QC subcommittee.
The final checklist approved by the panel group was presented to an examiner team, whose members had no previous encounter with the research topic, to assess the face validity and understandability of the questions. In this step, content validity was numerically calculated using two indicators: Content Validity Index (CVI) and Content Validity Ratio (CVR). Items with CVI scores less than 0.7 were omitted. Considering that our expert team had 13 members, the acceptable CVR was designated above 0.56 based on the Lawshe “minimum CVR value”. The reliability of the checklist was verified based on Cronbach’s α.

Training courses

In this step, eight examiners were requested to designate the level of QC for each item of the checklist based on an organized guideline presented to them during two training courses. The examiner team consisted of individuals who were registrars, researchers, executive directors, quality experts, administrators, and supervisors who were familiar with the process of data registration. All examiners (n = 8) participated in the training courses with a total duration of four hours. Finally, the QC of each registry was separately checked by the examiners using the provided checklist. During the training courses, the executive director of the registry provided the related documents and reports and briefly explained data collection methods. All examiners were then asked to rate each QC dimension for the registry according to the checklist under the supervision of the head of the team. All examiners independently investigated the registry. In order to calculate the agreement between examiners, the checklist was completed twice for two of the registries (# 25 and #26) at an interval of three months between June and August 2021. The average of Kappa agreement obtained was beyond 80%, which is considered acceptable.

Quantitative phase: data collection

During the evaluation step, four examiner teams assessed the QC of the registries from August to November 2021. On the examination day, the executive director presented the annual reports of the registry to examiner teams. Then the registry was rated for different items available on the checklist.

Data quality dimensions

There is a need to accurately define and regularly monitor all QC dimensions, some of which have been well discussed and defined in various fields of medicine [17]. Comparability, completeness, and validity are considered key QC items in most registries [21]. In the present study, we focused on six QC areas to assess our DRSs, including 1) Comparability: intra-organizational consistency of data over time allowing for comparison [17]; 2) Completeness: the data collected matching the data expected to describe a specific entity [19]; 3) Timeliness: collecting and sharing data within a reasonable time to be used for intended purposes [11]; 4) Interpretability: ease of understanding the data [22]; 5) Accessibility: ease of access to the data; users’ being informed of what data are being collected and where they are located; and 6) Validity: adhering to the rules or definitions applicable to the data during data collection [2].
A rating scale of 0 to 650 was used to rank the data during quality analysis. This rating scale was then transformed into a percentage system from 0 (the lowest quality) to 100% (the highest quality). A cut-point of 70% of the mean score based on a consensus reached by the panel group was considered desirable for different QC domains, including completeness, timeliness, accessibility, validity, comparability, and interpretability, whose individual cut-points were obtained as 111.3, 45.8, 70.4, 26.3, 5.6, and 20.57, respectively.

Results

During the study’s qualitative phase, a total of 29 items were extracted corresponding to the goals of the Ministry of Health and according to the literature in order to rank the quality of each registry. A satisfactory level of agreement was observed among the panelists with regard to the final 23 QC items. Regarding content validity assessment, the CVI and CVR of these 23 items were 0.79 and 0.58, respectively, suggesting the good content validity of the checklist items. Cronbach’s alpha coefficients for all QC domains were higher than 0.69, indicating acceptable internal consistency. This checklist was used to evaluate six QC domains for DRSs, including completeness (Q1, Q2, Q3, Q5, Q6, Q7, Q10, Q17, and Q18), timeliness (Q11, Q21, and Q22), accessibility (Q12, Q20, and Q23), validity (Q9, Q13, and Q14), comparability (Q16), and interpretability (Q4). These dimensions were ranked based on the total scores from the summing of related questions. Furthermore, data duplication, confidentiality, and understanding of the memorandum (MOU) were separately evaluated by the questions of Q8, Q15, and Q19, respectively (Table 1).
Table 1
Quality control checklist for disease registry programs
https://static-content.springer.com/image/art%3A10.1186%2Fs12913-023-09605-2/MediaObjects/12913_2023_9605_Tab1_HTML.png
During the study’s quantitative phase, the registries were assigned specific serial numbers. An overview of the 49 registries approved by SBMU has been shown in Table 2. Most of the registries (81.6%, n = 40) were focused on diagnosis/treatment; six of them (12.2%) recorded treatment outcomes and other registries were related to different scopes of diagnosis (n = 1,#49), procedures (n = 1, #47), and side effects of treatments (n = 1, #30). As illustrated in Fig. 1, most of the registries were in the field of neurology (n = 8), followed by pediatrics (n = 7) and cancer management (n = 6).
Table 2
Overview of 49 quality control registry’s in Shahid Beheshti University of medical science
Serial No
Registry name
Registry field
Registry subfield
Participation in healthcare units
Year of establishment
Level
Coverage area
Last cumulative report of registered cases
Neurology
 #1
Parkinson's Disease Registry in Patients Referred to Neurology Clinics of SBMU-PDR
Neurology
Diagnosis-Treatment
Outpatient
2019
National
• Tehran, SBMU
• Ilam
• Semnan
• Zabol
• Isfahan
• Ardabil
• Izeh
1000
 #2
Iranian Registry of Patients with Spinal Muscular Atrophy (SMA)
Physical Medicine and Rehabilitation
Diagnosis-Treatment
Outpatient
2020
Regional
• Tehran, SBMU
• Tehran, IMU
19
 #3
Brachial Plexus Damages Patients, Records In 15thkhordad Hospital /Tehran /Iran
Plastic & Reconstructive Surgery
Diagnosis-Treatment
Inpatient
2019
Regional
• Tehran, SBMU
116
 #4
Multiple Sclerosis
Neurology
Diagnosis-Treatment
Outpatient
2014
Regional
• Tehran, SBMU
• Karj, AMU
-
 #5
Iranian Registry of Neuro-metabolic Disease
Pediatric Neurology
Diagnosis-Treatment
Outpatient
2012
National
• Tehran, SBMU
• Tehran, TMU
• Tabriz, TMU
• North Khorasan University of Medical Sciences
• Isfahan,
250
 #6
Registry of patients with Neurocutaneous syndromes
Pediatric Neurology
Diagnosis-Treatment
Inpatient
2020
Regional
• Tehran, SBMU
55
 #7
Registry of Refractory Epilepsy in Iranian Children
Pediatric Neurology
Diagnosis-Treatment
Outpatient
2019
Regional
Shahid Beheshti University of Medical Sciences
180
 #8
The National Pediatric Migraine Registry
Pediatric Neurology
Diagnosis-Treatment
Outpatient
2020
Regional
• Tehran, SBMU
• Tehran, TMU
130
Serial No
Registry name
Registry field
Registry subfield
Participation in healthcare units
Year of establishment
Level
Coverage area
Last cumulative report of registered cases
Cancer
 #9
Cancer registry Using GIS system
Pulmonary Diseases
Treatment
Outpatient
2010
Regional
• Tehran, SBMU
-
 #10
Breast cancer clinical registry in Iran
Surgical Oncology
Diagnosis-Treatment
Outpatient
2000
Regional
• Tehran, SBMU
1000
 #11
Thyroid nodule and differentiated thyroid cancer registry
Endocrinology & Metabolism
Diagnosis-Treatment
Inpatient
2020
Regional
• Tehran, SBMU
96
 #12
Monitoring of intra-oral potentially malignant disorders
Oral & Maxillofacial Medicine
Diagnosis-Treatment
Outpatient
2020
National
• Tehran, SBMU
• Tehran, BMU
• Birjand,
• Babol
• Zahedan
130
 #13
Colorectal Cancer Registry System
Gastroenterology and Hepatology
Diagnosis-Treatment
Inpatient
2020
Regional
• Tehran, SBMU
450
 #14
Pancreatic Cancer Registry System
Gastroenterology and Hepatology
Diagnosis-Treatment
Inpatient
2020
Regional
• Tehran, SBMU
250
Respiratory
 #15
National registry program of Post Intubation Tracheal Intubation
Thoracic Surgery
Treatment
Inpatient
211
National
• Tehran, SBMU
3000
 #16
Chronic Obstructive Pulmonary Diseases Registry in Masih Daneshvari Hospital
Pulmonary Diseases
Treatment
Inpatient
2017
Regional
• Tehran, SBMU
-
 #17
Iranian-based registry for pulmonary arterial hypertension: Using GIS system
Pulmonary Diseases
Treatment
Outpatient
2010
Regional
• Tehran, SBMU
846
 #18
Bronchopulmonary dysplasia patients registration system in hospitals
Neonatal-Perinatal Medicine
Diagnosis-Treatment
Inpatient
2020
Regional
• Tehran, SBMU
100
Serial No
Registry name
Registry field
Registry subfield
Participation in healthcare units
Year of establishment
Level
Coverage area
Last cumulative report of registered cases
Urology
 #19
Registry of patients with urinary system stones
Urology
Diagnosis-Treatment
Outpatient
2020
Regional
• Tehran, SBMU
4638
 #20
Recurrent Urinary Tract Infection in Children
Pediatric Nephrology
Diagnosis-Treatment
Outpatient
2020
Regional
• Tehran, SBMU
83
 #21
Pediatric nephrotic syndrome children
Pediatric Nephrology
Diagnosis-Treatment
Inpatient
2020
Regional
• Tehran, SBMU
80
 #22
A national registry system for patients undergone Reconstructive Urologic procedures
Urology
Diagnosis-Treatment
Inpatient
1997
National
• Tehran, SBMU
• Urmia
• Ahvaz
• Tabriz
• Mashhad
2700
Orthopedic
 #23
Database registry for hip arthroplasty
Hip & Pelvis Surgery
Diagnosis-Treatment
Inpatient
2020
Regional
• Tehran, SBMU
80
 #24
Database registry for knee arthroplasty
Orthopedics
Diagnosis-Treatment
Inpatient
2020
Regional
• Tehran, SBMU
79
Ophthalmology
 #25
The National Registry for Keratoconus in Iran
Cornea & External Eye Diseases
Diagnosis-Treatment
Outpatient
2019
Regional
• Tehran, SBMU
600
 #26
The First Database Registry for Hereditary Retinal Dystrophies and Degenerations in Iran
Retina & Vitreous
Treatment
Outpatient
2016
National
• Tehran, SBMU
• Tehran, TMU
• Tehran, IMU
• Ahvaz
• Tabriz
• Mashhad
• Isfahan
• Yazd
2100
Serial No
Registry name
Registry field
Registry subfield
Participation in healthcare units
Year of establishment
Level
Coverage area
Last cumulative report of registered cases
Neonatal
 #27
Kernicterus registry system in the hospitals
Neonatal-Perinatal Medicine
Diagnosis-Treatment
Inpatient/ Outpatient
2021
Regional
• Tehran, SBMU
-
 #28
Neonatal thrombosis registration system
Neonatal-Perinatal Medicine
Diagnosis-Treatment
Inpatient
2020
Regional
• Tehran, SBMU
26
 #29
Very Low Birth Weight Infants Registration system
Neonatal-Perinatal Medicine
Diagnosis-Treatment
Inpatient
2020
Regional
• Tehran, SBMU
200
 #30
Register the BCG vaccine complications in pediatric
Vaccination
Side effects
Outpatient (PHC)
2019
Regional
• Tehran, SBMU
16
Pediatric
 #31
Iranian Registry of Pediatric Inflammatory Bowel Disease (PIBD)
Pediatrics Gastroenterology
Diagnosis-Treatment
Outpatient
2019
National
• Tehran, SBMU
• Babol
• Hamedan
• Urmia
• Isfahan
• Ilam
61
 #32
Registry of Pediatric Wilson Disease
Pediatrics Gastroenterology
Diagnosis-Treatment
Outpatient
2020
National
• Tehran, SBMU
• Babol
• Hamedan
• Urmia
• Isfahan
• Ilam
• Ghom
107
 #33
Registry of pediatric autoimmune hepatitis
Pediatrics Gastroenterology
Diagnosis-Treatment
Outpatient
2019
National
• Tehran, SBMU
• Babol
• Hamedan
• Urmia
• Isfahan
• Ilam
• Ghom
56
Serial No
Registry name
Registry field
Registry subfield
Participation in healthcare units
Year of establishment
Level
Coverage area
Last cumulative report of registered cases
 #34
Iranian Registry of pediatric endoscopy databases system clinical outcomes research initiative procedures and liver biopsy
Pediatrics Gastroenterology
Diagnosis-Treatment
Inpatient
2019
National
• Tehran, SBMU
• Babol
• Hamedan
• Urmia
• Isfahan
• Ilam
702
 #35
Registry system of Autistic patients
Pediatrics Neurology
Diagnosis-Treatment
Outpatient
2021
Regional
• Tehran, SBMU
50
 #36
Pediatric Liver Failure (pALF) Registration System in Iran
Pediatrics Gastroenterology
Diagnosis-Treatment
Outpatient
2019
National
• Tehran, SBMU
• Babol
• Hamedan
• Urmia
• Isfahan
• Ilam
28
 #37
Registry system for evaluation of childhood fatty liver in Iran
Nutritional Sciences
Diagnosis-Treatment
Inpatient
2019
Regional
• Tehran, SBMU
19
Obesity & Diet
 #38
Registry of ketogenic diets
Pediatric Neurology
Treatment
Outpatient
2020
National
• Tehran, SBMU
• Tehran, TMU
• Tabriz
• Isfahan
87
 #39
Registry system for evaluation of childhood Obesity in Iran
Pediatrics Gastroenterology
Diagnosis-Treatment
Outpatient
2019
National
• Tehran, SBMU
• Babol
• Hamedan
• Urmia
• Isfahan
• Ilam
• Ghom
158
 #40
Registry system for evaluation of the malnutritional status of children and adolescents hospitalized in Iran (1 month to 18 years)
Nutritional Sciences
Diagnosis-Treatment
Inpatient
2019
National
• Tehran, SBMU
• Babol
• Hamedan
• Urmia
• Isfahan
• Ilam
• Ghom
63
Serial No
Registry name
Registry field
Registry subfield
Participation in healthcare units
Year of establishment
Level
Coverage area
Last cumulative report of registered cases
 #41
Registration of patients in Tehran Obesity Treatment Center
Obesity
Diagnosis-Treatment
Inpatient
2014
Regional
• Tehran, SBMU
4600
Hematology
 #42
Data registry of Hematopoietic Stem Cell Transplantation in pediatrics group (0–18 years old)
Pediatric Hematology and Oncology
Diagnosis-Treatment
Inpatient
2020
Regional
• Tehran, SBMU
129
 #43
Regional Registry of Pediatric Immune Thrombocytopenic Purpura
Pediatric Hematology and Oncology
Diagnosis-Treatment
Inpatient
2020
Regional
• Tehran, SBMU
10
 #44
Registry of thromboembolism events in pediatrics group (up to15 years)
Pediatric Hematology and Oncology
Diagnosis-Treatment
Inpatient
2020
Regional
Shahid Beheshti University of Medical Sciences
25
Poisoning
 #45
Poisoning information registry system
Pediatrics Poisoning
Diagnosis-Treatment
Inpatient
2021
Regional
• Tehran, SBMU
90
 #46
Iranian Registry of Pediatric Lead Poisoning
Pediatrics Gastroenterology
Diagnosis-Treatment
Inpatient
2019
National
• Tehran, SBMU
• Babol
• Hamedan
• Urmia
• Isfahan
• Ilam
97
Gastroenterology
 #47
Establishment of Registry System for ERCP (Endoscopic Retrograde Cholangio Pancreatography)
Gastroenterology and Hepatology
Procedure
Inpatient
2020
Regional
• Tehran, SBMU
1400
Gynecology
 #48
Premature ovarian failure
Gynecology
Diagnosis-Treatment
Outpatient
2020
Regional
• Tehran, SBMU
200
Muscle Biopsy
 #49
Registry of Patients Referred for Muscle Biopsy
Muscle Biopsy
Diagnosis
Outpatient
2020
Regional
• Tehran, SBMU
5000
Table 3 shows the ranking of the registries studied based on their QC scores. The highest rank (96.1%) belonged to registries #22 and #42, and the lowest ranking (20%) was related to registry #49.
Table 3
Total score and rank obtained of disease registry programs of Shahid Beheshti University of Medical Sciences in 2021
Serial No
Registry program title
Total score
Score of 100
Ranking
#42
Data registry of Hematopoietic Stem Cell Transplantation in pediatrics group (0–18 years old)
625
96.1
1
#22
A national registry system for patients undergoing reconstructive urologic procedures
625
96.1
1
#43
Regional Registry of Pediatric Immune Thrombocytopenic Purpura
615
94.6
2
#44
Registry of thromboembolism events in pediatrics group (up to15 years)
605
93.1
3
#40
Registry system for evaluation of the malnutritional status of children and adolescents hospitalized in Iran (1 month to 18 years)
605
93.1
3
#36
Pediatric Liver Failure (pALF) Registration System in Iran
605
93.1
3
#41
Registration of patients in Tehran Obesity Treatment Center
605
93.1
3
#2
Iranian Registry of Patients with Spinal Muscular Atrophy (SMA)
605
93.1
3
#10
Breast cancer clinical registry in Iran
600
92.3
4
#39
Registry system for evaluation of childhood Obesity in Iran
590
90.1
5
#20
Recurrent Urinary Tract Infection in Children
585
90.0
6
#12
Monitoring of intra-oral potentially malignant disorders
585
90.0
6
#15
National Registry program of Post Intubation Tracheal Intubation (ALBORZ database)
580
89.2
7
#25
The National Registry for Keratoconus in Iran
575
88.4
8
#21
Pediatric nephrotic syndrome children
570
87.7
9
#18
Bronchopulmonary dysplasia patients registration system in hospitals
565
86.9
10
#8
The National Pediatric Migraine Registry
565
86.9
10
#26
The First Database Registry for Hereditary Retinal Dystrophies and Degenerations in Iran
555
85.4
11
#29
Very Low Birth Weight Infants Registration system
550
84.6
12
#38
Registry of ketogenic diets
545
83.8
13
#23
Database registry for hip arthroplasty
540
83.1
14
#33
Registry of pediatric autoimmune hepatitis
505
77.7
15
#37
Registry system for evaluation of childhood fatty liver in Iran
495
76.1
16
#28
Neonatal thrombosis registration system
490
75.3
17
#32
Registry of Pediatric Wilson Disease
480
73.8
18
#34
Iranian Registry of pediatric endoscopy databases system clinical outcomes research initiative procedures and liver biopsy
480
73.8
18
#17
Iranian-based registry for pulmonary arterial hypertension: Using GIS system
475
73.1
19
#46
Iranian Registry of Pediatric Lead Poisoning
470
72.3
20
#1
Parkinson's Disease Registry in Patients Referred to Neurology Clinics of SBMU-PDR
470
72.3
20
#35
Registry system of Autistic patients
440
67.7
21
#6
Registry of patients with Neurocutaneous syndromes
435
66.9
22
#3
Brachial Plexus Damages Patients, Records In 15thkhordad Hospital /Tehran /Iran
420
64.6
23
#16
Chronic Obstructive Pulmonary Diseases Registry
410
63.1
24
#24
Database registry for knee arthroplasty
400
61.5
25
#30
Register the BCG vaccine complications in pediatric
390
60.0
26
#7
Registry of Refractory Epilepsy in Iranian Children
375
57.7
27
#45
Poisoning information registry system
370
56.9
28
#31
Iranian Registry of Pediatric Inflammatory Bowel Disease (PIBD)
370
56.9
28
#14
Pancreatic Cancer Registry System
350
53.8
29
#27
Kernicterus registry system in the hospitals
340
52.3
30
#5
Iranian Registry of Neuro-metabolic Disease
315
48.5
31
#47
Establishment of Registry System for ERCP (Endoscopic Retrograde Cholangio Pancreatography)
310
47.7
32
#13
Colorectal Cancer Registry System
310
47.7
32
#4
Multiple Sclerosis
305
46.9
33
#48
Premature ovarian failure
285
43.8
34
#11
Thyroid nodule and differentiated thyroid cancer registry
265
40.7
35
#9
Cancer registry Using GIS system
260
40.0
36
#19
Registry of patients with urinary system stones
190
29.2
37
#49
Registry of Patients Referred for Muscle Biopsy
130
20.0
38
Table 4 presents the mean score of each QC domain for DRSs based on the total scores from the summing of related questions. Regarding the acceptable quality cut-point (i.e., > 70% of the mean score of each domain), out of 49 DRSs evaluated, 48 (98%), 46 (94%), 41 (84%), 38 (77.5%), 36 (73.5%), and 32 (65.3%) registries obtained quality scores in the domains of interpretability, accessibility, completeness, comparability, timeliness, and validity, respectively. In this study, the rate of recording duplicated data was low (12.2%), which can be explained by the development of electronic registries with unique national ID numbers.
Table 4
Scores of six domains of quality control of 49 registries
Serial No
Registry Title
Comparability
Completeness
Timeliness
Accessibility
Interpretability
validity
 
Mean score of each domain of 49 registries ± SD
7.9 ± 3.7
159.0 ± 56.0
65.4 ± 29.5
100.5 ± 25.0
29.4 ± 4.3
37.6 ± 27.1
 
70% of the mean score as cut-point
5.6
111.3
45.8
70.4
20.6
26.3
#1
Parkinson's Disease Registry in Patients Referred to Neurology Clinics of Shahid Beheshti University of Medical Sciences in Tehran (SBMU-PDR)
10
135
85
100
30
15
#2
Iranian Registry of Patients with Spinal Muscular Atrophy (SMA)
5
210
90
110
30
65
#3
Brachial Plexus Damages Patients, Records In 15thkhordad Hospital /Tehran /Iran
10
145
90
110
30
0
#4
Multiple Sclerosis
10
130
0
100
30
0
#5
Iranian Registry of neurometabolic patients
10
110
35
10
30
50
#6
Registry of patients with Neurocutaneous syndromes
10
180
20
110
30
50
#7
Registry of Refractory Epilepsy in Iranian Children
10
130
30
110
30
30
#8
The National Pediatric Migraine Registry
10
205
85
110
30
50
#9
Establishment of Cancer Registry in Masih Daneshvari Hospital: Using GIS system
0
50
55
100
30
15
#10
Establishment of Breast cancer clinical registry in Iran
10
225
85
110
30
45
#11
Thyroid nodule and differentiated thyroid cancer registry
0
55
5
100
30
0
#12
Setting up of a registry system and monitoring of intra-oral potentially malignant disorders in Shahid Beheshti Dental School
10
210
80
110
30
50
#13
Establishment of colorectal cancer Registry System
0
95
60
100
30
0
#14
Establishment of Pancreatic Cancer Registry System
0
125
60
100
30
0
#15
National registry program of Post Intubation Tracheal Stenosis (ALBORZ database)
5
225
85
110
30
90
#16
Chronic Obstructive Pulmonary Diseases Registry in Masih Daneshvari Hospital
10
180
30
100
30
50
#17
Iranian-based registry for pulmonary arterial hypertension: Using GIS system
10
185
85
100
30
30
#18
Establishment of bronchopulmonary dysplasia patients registration system in hospitals of Shahid Beheshti University of Medical Sciences
10
200
85
110
30
45
Serial No
Registry Title
Comparability
Completeness
Timeliness
Accessibility
Interpretability
validity
#19
Registry of patients with urinary system stones
10
55
0
75
0
15
#20
Recurrent Urinary Tract Infection in Children
5
205
85
110
30
65
#21
Pediatric nephrotic syndrome
10
205
90
110
30
30
#22
Establishment of a national registry system for patients undergone Reconstructive Urologic procedures
10
225
90
110
30
65
#23
Establishment of the database registry for hip arthroplasty
10
205
85
110
30
65
#24
Establishment of the database registry for knee arthroplasty
10
115
85
110
30
15
#25
The National Registry for Keratoconus in Iran
10
180
85
110
30
65
#26
Establishment of the First Database Registry for Hereditary Retinal Dystrophies and Degenerations in Iran
10
145
75
110
30
90
#27
Establishment of a kernicterus registry system in the hospitals affiliated with Shahid Beheshti University of Medical Sciences
10
80
30
100
30
15
#28
Establishment of the neonatal thrombosis registration system in Shahid Beheshti University of Medical Sciences
10
125
75
110
30
45
#29
Establishment of Very Low Birth Weight Infants Registration system
10
225
75
110
30
15
#30
Register the BCG vaccine complications in pediatric
10
145
60
110
30
65
#31
Iranian Registry of Pediatric Inflammatory Bowel Disease (PIBD)
10
95
10
110
30
45
#32
Registry of Pediatric Wilson Disease
10
145
90
110
30
0
#33
Registry of pediatric autoimmune hepatitis
10
180
25
110
30
50
#34
Iranian Registry of pediatric endoscopy databases system clinical outcomes research initiative procedures and liver biopsy
10
120
85
110
30
30
#35
Registry system of Autistic patients
10
180
25
110
30
50
#36
Establishment of Pediatric Liver Failure (pALF) Registration System in Iran
10
205
90
110
30
65
#37
Registry system for evaluation of childhood fatty liver in Iran
10
205
90
110
30
65
#38
Registry of ketogenic diets
5
190
90
110
30
50
#39
Registry system for evaluation of childhood Obesity in Iran
10
195
85
110
30
65
#40
Registry system for evaluation of the malnutritional status of children and adolescents hospitalized in Iran (1 month to 18 years)
10
210
85
110
30
65
#41
Registration of patients in Tehran Obesity Treatment Center
10
225
90
110
30
65
Serial No
Registry Title
Comparability
Completeness
Timeliness
Accessibility
Interpretability
validity
#42
Data registry of Hematopoietic Stem Cell Transplantation in pediatrics group (0–18 years old) in Shahid Beheshti University of Medical Sciences and Allied centers
10
225
90
110
30
65
#43
Regional Registry of Pediatric Immune Thrombocytopenic Purpura
10
215
90
110
30
65
#44
Data registry of thromboembolism events in pediatrics group (up to15 years) in Mofid Children`s Hospital and allied centers hospital in Iran
10
125
75
110
30
45
#45
Designing and Implementation of poisoning information registry system
0
150
55
100
30
0
#46
Iranian Registry of Pediatric Lead Poisoning
5
140
90
110
30
0
#47
Establishment of Registry System for ERCP (Endoscopic Retrograde CholangioPancreatography)
0
120
10
100
30
15
#48
premature ovarian failure
10
180
30
10
30
15
#49
Registry of Patients Referred for Muscle Biopsy
0
25
50
0
30
0

Discussion

In this study, we developed a customized checklist to assess six quality domains in 49 DRSs established by SBMU in 2021. Our results demonstrated that all the registries had acceptable interpretability, accessibility, comparability, and completeness. In addition, the timeliness and validity domains acquired the lowest quality ranks.
There are several methodological problems with data quality assessment, one of which is the lack of a comprehensive standardized method for this purpose. The quality of data varies between different practices, and data quality needs to be assessed based on unique requirements in various fields [21, 23, 24]. Comparability, completeness, and validity are considered key elements during data quality assessment [21, 23]. Faulconer and de Lusignan suggested an 8-step statistical method for assessing the quality of the data of patients with chronic obstructive pulmonary disease [24]. Therefore, we developed a specific checklist to assess the QC of our DRSs in different fields.
Only a high degree of completeness will ensure that the incidence and prevalence rates estimated in DRSs are close to their ‘true’ values. Most data QC dimensions overlap with each other, and their interpretations are vague due to ambiguous definitions or even a lack of standard definitions. Two of the most frequently cited data QC dimensions are “accuracy” and “completeness”. It may be difficult to accurately estimate the completeness of registries because this entity is influenced by the proportion of patients introduced to registries by healthcare centers, the ratio of those refusing to be referred, and the total number of patients in the study population [25]. In our investigation, the overall rate of completeness was obtained at 84%, which was in line with the study conducted by Fung et al. on Singapore’s cancer registries, reporting a completeness rate of 98.1% [26]. One possible reason for lower completeness in some of our DRSs may be the short time passing from their establishment (#11, #19, and #27). Despite all the limitations such as the relatively short period of the study, in a study by Lee et al., completeness of 90–100% was reported for a registry of operative sectors (e.g., operating surgeons, consulting surgeons, and the hospital). Interestingly, auditing revealed that the registry’s completeness reached 100% after resolving deficiencies [27]. Another explanation for this variation in completeness may be differences in the number of patients with specific disorders such as Parkinson's disease (#1), SMA (#2), pediatric migraine (#8), tracheal stenosis following intubation (#15), and pediatric nephrotic syndrome (#21). In addition, nationwide recruitment for a number of our registries (#42, #43, and #44) could have contributed to their high completeness rates. Also, some medical procedures should be registered before their costs can be reimbursed by insurance companies (registries #12, #23, and #24). Another factor increasing the completeness of data recording can be the proven utility of this practice amongst health professionals in the registeration centers (#10, #18, #22, #36, #37, and #41). It is worth noting that using this checklist, we were unable to determine the proportion of eligible patients who decided not to be enlisted in relevant registries, increasing the likelihood of overestimating completeness in these registries.
Using standard internationally approved definitions for recording and reporting data boosts the level of comparability of registries [11]. In our study, there was limited standardization regarding the definitions used in registries, leading 11 out of 49 registries to have unacceptable comparability in terms of diagnostic and therapeutic elements. It is worth mentioning that in our checklist, only one question (Q16) was related to comparability, limiting the ability of this checklist to reliably assess this quality domain compared to other dimensions investigated by multiple questions. Comparability has been reported to vary considerably in different registries. In a study in Russia, only four cancer registries out of 10 studied registries met international standards [28]. However, cancer registries in Singapore were reported to have a high level of comparability [26]. Low comparability is the main barrier to achieving an interoperability framework, and one potential solution to this problem is to develop a team of specialists and experts to standardize definitions across all DRSs.
High timeliness allows for the real-time recording of diagnoses, procedures, and other relevant data in DRSs. Although there are currently no international regulations for assessing timeliness, timely reporting of information is a foremost priority for all registries [1, 11]. There are rare reports on the timeliness of DRSs [29], and the definition of this term in the context of data registries should be exactly determined. In general, timeliness refers to the rapidity at which a registry can collect, process, and report reliable and complete data [30]. In our checklist, timeliness was defined as the date on which the database was ‘frozen’ to calculate annual statistics for issuing an official report. This period comprised two intervals: the time until receipt announcement (ie., from the date of diagnosis to the day of receiving the report) and the processing time (i.e., from the date of report receiving until data availability). In our report, in 36 out of 49 registries (73.5%), physicians or nurses reported the data at the time of patient visits or shortly afterward, but five registries had delays in submitting annual reports. Also, eight of the registries preferred to postpone the publication of their results to attain better completeness to the cost of undesirable timeliness. Evaluating the timeliness and several other quality dimensions of a pediatric mortality surveillance system in Iran showed that this system successfully fulfilled timeliness criteria mainly because the managers were committed to holding a monthly committee for monitoring childhood mortality and the immediate reporting of infectious diseases [31]. Moreover, an evaluation of timeliness at the Cancer Registry of Norway during 1953–2005 showed that the median time for diagnosis of a new case reduced from over 525 days in 2001 to 261 days in 2005 [29]. Another study showed that the timeliness of the diseases was low based on the national reporting of the disease surveillance system [32]. Therefore, implementing electronic data recording and employing dedicated and well-trained staff can improve the timeliness of registries in reporting their data.
Accessibility is defined as the ease of access to data for users, rendering the data more available and making it possible for others to confirm the registry’s results [33]. As almost all of our registries used the same unique software, they acquired high accessibility (94%). This unique software facilitates the generation of meaningful and credible information from diverse sources, decreasing the occurrence of potential errors during the data entry process and facilitating access to the data. In line with our results, a study by Azadmanjir et al. aimed to identify and address hurdles to data accessibility at the National Spinal Cord Injury Registry of Iran, a registry relying on primary data sources. Their expert panel selected 174 data quality items, including accessibility and usefulness in quality-of-care assessment in emergency settings [34].
Validity is the extent to which the data registered can be assessed in terms of accuracy and relevant rules or definitions [35]. A high validity rate (91.9%) was reported for Singapore’s cancer registries, which could be attributed to the fact that these registries were focused on a specific field [26]. In the present study, nearly one-third of our registries (35%) had low validity, mainly due to the lack of uniform definitions for items due to the variety of DRS fields. This observation highlights the importance of employing uniform, transparent, and accurate definitions by all registries according to existing guidelines and classifications.
Interpretability is defined as the ease of understanding of data for users, presenting one of the main challenges faced by data registries and requiring a clinical framework for data interpretation and scoring [2]. Registered data can be interpreted only if they are specifically assigned to exact endpoints [22]. In our checklist, this quality domain was assessed by a single question (Q4), asking about the presence or absence of a data dictionary at each registry, and almost all (98%) of the registries investigated obtained a score higher than the cut-point. There are no previous reports on the interpretability of registered data in DRSs, so we could not compare our observation with other studies in terms of this QC domain.
The main strength of the present investigation included the development of a customized checklist to assess data quality in Iran’s DRSs in various fields in terms of all main QC standard indicators. One of the limitations of this study was that we confined our search to DRSs established by SBMU in Tehran, which could decrease the generalizability of our findings. Second, most of these DRSs mainly rely on the reports generated by governmental hospitals, and it is possible that the private hospitals or health service centers in different regions might not be covered.

Conclusion

In this study, a customized checklist was developed to assess the quality of the data recorded in DRSs, which could be considered a proof of concept for future investigations. Our results demonstrated that most of DRSs had high degrees of interpretability, accessibility, comparability, and completeness. However, their timeliness and validity needed to be improved. As the DRSs of the SBMU acquired a high degree of quality control in most of the studied domains allows for greater confidence in the use of the qualified data to improve the healthcare system and the possibility of integrating data with national healthcare data.

Acknowledgements

Authors thank the hospitals and research centers staff, assistants, and coordinators who participated in this research.

Declarations

All the procedures performed in the study were approved by the Research Ethics Committee of the Research Institute for Endocrine Sciences of Shahid Beheshti University of Medical Sciences and were in accordance with the ethical standards of the institutional Human Research Review Committee (No. IR.SBMU.RETECH.REC.1400.577) and the 1964 Helsinki declaration and its later amendments. Informed written consent was obtained from all participants.
Not applicable.

Competing interests

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat McGilvray D. Executing data quality projects: ten steps to quality data and trusted information (TM): Academic Press; 2021. McGilvray D. Executing data quality projects: ten steps to quality data and trusted information (TM): Academic Press; 2021.
2.
Zurück zum Zitat Gliklich RE, Dreyer NA, Leavy MB. Registries for evaluating patient outcomes: a user’s guide. 2014. Gliklich RE, Dreyer NA, Leavy MB. Registries for evaluating patient outcomes: a user’s guide. 2014.
3.
Zurück zum Zitat Andersen MR, Schroeder T, Gaul M, Moinpour C, Urban N. Using a population-based cancer registry for recruitment of newly diagnosed patients with ovarian cancer. Am J Clin Oncol. 2005;28(1):17–20.CrossRefPubMed Andersen MR, Schroeder T, Gaul M, Moinpour C, Urban N. Using a population-based cancer registry for recruitment of newly diagnosed patients with ovarian cancer. Am J Clin Oncol. 2005;28(1):17–20.CrossRefPubMed
4.
Zurück zum Zitat Brooke EM, Organization WH. The current and future use of registers in health information systems: World Health Organization; 1974.https://www.who.in. Brooke EM, Organization WH. The current and future use of registers in health information systems: World Health Organization; 1974.https://​www.​who.​in.
5.
6.
Zurück zum Zitat Kohanim S, Sternberg P. Ophthalmic patient data registries: defining and improving quality and outcomes. Ophthalmology. 2014;121(3):619–21.CrossRefPubMed Kohanim S, Sternberg P. Ophthalmic patient data registries: defining and improving quality and outcomes. Ophthalmology. 2014;121(3):619–21.CrossRefPubMed
7.
Zurück zum Zitat Girman CJ, Ritchey ME. Pragmatic Randomized Clinical Trials: Using Primary Data Collection and Electronic Health Records: Academic Press; 2021. Girman CJ, Ritchey ME. Pragmatic Randomized Clinical Trials: Using Primary Data Collection and Electronic Health Records: Academic Press; 2021.
8.
Zurück zum Zitat Nour S, Plourde G. Pharmacoepidemiology in the prevention of adverse drug reactions. Pharmacoepidemiology and Pharmacovigilance. 2019. p. 25–65.CrossRef Nour S, Plourde G. Pharmacoepidemiology in the prevention of adverse drug reactions. Pharmacoepidemiology and Pharmacovigilance. 2019. p. 25–65.CrossRef
9.
Zurück zum Zitat Kölker S, Gleich F, Mütze U, Opladen T. Rare disease registries are key to evidence-based personalized medicine: highlighting the european experience. Front Endocrinol (Lausanne). 2022;13:832063.CrossRefPubMed Kölker S, Gleich F, Mütze U, Opladen T. Rare disease registries are key to evidence-based personalized medicine: highlighting the european experience. Front Endocrinol (Lausanne). 2022;13:832063.CrossRefPubMed
10.
Zurück zum Zitat Whitney CW, Lind BK, Wahl PW. Quality assurance and quality control in longitudinal studies. Epidemiol Rev. 1998;20(1):71–80.CrossRefPubMed Whitney CW, Lind BK, Wahl PW. Quality assurance and quality control in longitudinal studies. Epidemiol Rev. 1998;20(1):71–80.CrossRefPubMed
11.
Zurück zum Zitat Bray F, Parkin DM. Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer. 2009;45(5):747–55.CrossRefPubMed Bray F, Parkin DM. Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer. 2009;45(5):747–55.CrossRefPubMed
12.
Zurück zum Zitat Parkin DM, Bray F. Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness Eur J Cancer. 2009;45(5):756–64.CrossRefPubMed Parkin DM, Bray F. Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness Eur J Cancer. 2009;45(5):756–64.CrossRefPubMed
13.
Zurück zum Zitat Najafi A, Bagherifard A, Kaseb MH, Mortazavi SM, Mansouri P. National Joint Registry of Iran. Arch Bone Jt Surg. 2019;7(1):75–8.PubMedPubMedCentral Najafi A, Bagherifard A, Kaseb MH, Mortazavi SM, Mansouri P. National Joint Registry of Iran. Arch Bone Jt Surg. 2019;7(1):75–8.PubMedPubMedCentral
14.
Zurück zum Zitat Salehi Z, Almasi-Hashiani A, Sahraian MA, Ashtari F, Baghbanian SM, Razazian N, et al. Epidemiology of familial multiple sclerosis in Iran: a national registry-based study. BMC Neurol. 2022;22(1):76.CrossRefPubMedPubMedCentral Salehi Z, Almasi-Hashiani A, Sahraian MA, Ashtari F, Baghbanian SM, Razazian N, et al. Epidemiology of familial multiple sclerosis in Iran: a national registry-based study. BMC Neurol. 2022;22(1):76.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Alvand S, Roshandel G. Pancreatic Cancer in Iran - Result of the Iranian National Cancer Registry Program. Asian Pac J Cancer Prev. 2022;23(11):3825–31.CrossRefPubMedPubMedCentral Alvand S, Roshandel G. Pancreatic Cancer in Iran - Result of the Iranian National Cancer Registry Program. Asian Pac J Cancer Prev. 2022;23(11):3825–31.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Jazayeri SB, Saadat S, Ramezani R, Kaviani A. Incidence of primary breast cancer in Iran: ten-year national cancer registry data report. Cancer Epidemiol. 2015;39(4):519–27.CrossRefPubMed Jazayeri SB, Saadat S, Ramezani R, Kaviani A. Incidence of primary breast cancer in Iran: ten-year national cancer registry data report. Cancer Epidemiol. 2015;39(4):519–27.CrossRefPubMed
17.
Zurück zum Zitat Zaletel M, Kralj M, Magajne M, Doupi P. Methodological guidelines and recommendations for efficient and rational governance of patient registries. Ljubljana: National Institute of Public Health; 2015. p. 17–39. Zaletel M, Kralj M, Magajne M, Doupi P. Methodological guidelines and recommendations for efficient and rational governance of patient registries. Ljubljana: National Institute of Public Health; 2015. p. 17–39.
18.
Zurück zum Zitat M Avdicova. Data quality monitoring and surveillance system evaluation: A handbook of methods and applications. ECDC Technical Document; 2014. M Avdicova. Data quality monitoring and surveillance system evaluation: A handbook of methods and applications. ECDC Technical Document; 2014.
19.
Zurück zum Zitat Couchoud C, Lassalle M, Cornet R, Jager KJ. Renal replacement therapy registries—time for a structured data quality evaluation programme. Nephrol Dial Transplant. 2013;28(9):2215–20.CrossRefPubMed Couchoud C, Lassalle M, Cornet R, Jager KJ. Renal replacement therapy registries—time for a structured data quality evaluation programme. Nephrol Dial Transplant. 2013;28(9):2215–20.CrossRefPubMed
20.
Zurück zum Zitat Liu FX, Rutherford P, Smoyer-Tomic K, Prichard S, Laplante S. A global overview of renal registries: a systematic review. BMC Nephrol. 2015;16(1):1–10.CrossRef Liu FX, Rutherford P, Smoyer-Tomic K, Prichard S, Laplante S. A global overview of renal registries: a systematic review. BMC Nephrol. 2015;16(1):1–10.CrossRef
21.
Zurück zum Zitat Bray F, Kohler B, Ferlay J. Data comparability and quality. IARC Sci Publ. 2014;(164 Pt 1):89–106. Bray F, Kohler B, Ferlay J. Data comparability and quality. IARC Sci Publ. 2014;(164 Pt 1):89–106.
22.
Zurück zum Zitat Gliklich RE, Leavy MB, Dreyer NA. Analysis, interpretation, and reporting of registry data to evaluate outcomes. Registries for Evaluating Patient Outcomes: A User’s Guide. 4th ed. US: Agency for Healthcare Research and Quality; 2020.CrossRef Gliklich RE, Leavy MB, Dreyer NA. Analysis, interpretation, and reporting of registry data to evaluate outcomes. Registries for Evaluating Patient Outcomes: A User’s Guide. 4th ed. US: Agency for Healthcare Research and Quality; 2020.CrossRef
23.
Zurück zum Zitat Bhurgri Y, Bhurgri A, Hasan SH. Comparability and Quality Control in Cancer Registration; Karachi (data monitoring 1995–2001). J Pak Med Assoc. 2002;52(7):301–7.PubMed Bhurgri Y, Bhurgri A, Hasan SH. Comparability and Quality Control in Cancer Registration; Karachi (data monitoring 1995–2001). J Pak Med Assoc. 2002;52(7):301–7.PubMed
24.
Zurück zum Zitat Faulconer ER, de Lusignan S. An eight-step method for assessing diagnostic data quality in practice: chronic obstructive pulmonary disease as an exemplar. Inform Prim Care. 2004;12(4):243–54.PubMed Faulconer ER, de Lusignan S. An eight-step method for assessing diagnostic data quality in practice: chronic obstructive pulmonary disease as an exemplar. Inform Prim Care. 2004;12(4):243–54.PubMed
25.
Zurück zum Zitat Thygesen LC, Ersbøll AK. When the entire population is the sample: strengths and limitations in register-based epidemiology. Eur J Epidemiol. 2014;29(8):551–8.CrossRefPubMed Thygesen LC, Ersbøll AK. When the entire population is the sample: strengths and limitations in register-based epidemiology. Eur J Epidemiol. 2014;29(8):551–8.CrossRefPubMed
26.
Zurück zum Zitat Fung JW, Lim SB, Zheng H, Ho WY, Lee BG, Chow KY, et al. Data quality at the Singapore Cancer Registry: an overview of comparability, completeness, validity and timeliness. Cancer Epidemiol. 2016;43:76–86.CrossRefPubMed Fung JW, Lim SB, Zheng H, Ho WY, Lee BG, Chow KY, et al. Data quality at the Singapore Cancer Registry: an overview of comparability, completeness, validity and timeliness. Cancer Epidemiol. 2016;43:76–86.CrossRefPubMed
27.
Zurück zum Zitat Lee B, Ebrahimi M, Ektas N, Ting CH, Cowley M, Scholes C, et al. Implementation and quality assessment of a clinical orthopaedic registry in a public hospital department. BMC Health Serv Res. 2020;20(1):393.CrossRefPubMedPubMedCentral Lee B, Ebrahimi M, Ektas N, Ting CH, Cowley M, Scholes C, et al. Implementation and quality assessment of a clinical orthopaedic registry in a public hospital department. BMC Health Serv Res. 2020;20(1):393.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Barchuk A, Tursun-Zade R. Comparability and validity of cancer registry data in the northwest of Russia. Cancer Epidemiol. 2021;60(10):1264–71. Barchuk A, Tursun-Zade R. Comparability and validity of cancer registry data in the northwest of Russia. Cancer Epidemiol. 2021;60(10):1264–71.
29.
Zurück zum Zitat Larsen IK, Småstuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–31.CrossRefPubMed Larsen IK, Småstuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–31.CrossRefPubMed
30.
Zurück zum Zitat Zanetti R, Schmidtmann I, Sacchetto L, Binder-Foucard F, Bordoni A, Coza D, et al. Completeness and timeliness: cancer registries could/should improve their performance. Eur J Cancer. 2015;51(9):1091–8.CrossRefPubMed Zanetti R, Schmidtmann I, Sacchetto L, Binder-Foucard F, Bordoni A, Coza D, et al. Completeness and timeliness: cancer registries could/should improve their performance. Eur J Cancer. 2015;51(9):1091–8.CrossRefPubMed
31.
Zurück zum Zitat Bahardoust M, Rajabi A, Barakati S-H, Naserbakht M, Ghadami S, Talachian E, et al. Evaluation of timeliness, simplicity, acceptability, and flexibility in child mortality surveillance system for children aged 1–59 months in Iran. Int J Prev Med. 2019;10:205.CrossRefPubMedPubMedCentral Bahardoust M, Rajabi A, Barakati S-H, Naserbakht M, Ghadami S, Talachian E, et al. Evaluation of timeliness, simplicity, acceptability, and flexibility in child mortality surveillance system for children aged 1–59 months in Iran. Int J Prev Med. 2019;10:205.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Jajosky RA, Groseclose SL. Evaluation of reporting timeliness of public health surveillance systems for infectious diseases. BMC Public Health. 2004;4:29.CrossRefPubMedPubMedCentral Jajosky RA, Groseclose SL. Evaluation of reporting timeliness of public health surveillance systems for infectious diseases. BMC Public Health. 2004;4:29.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Cai L, Zhu Y. The challenges of data quality and data quality assessment in the big data era. Data Sci J. 2015;14:4–29.CrossRef Cai L, Zhu Y. The challenges of data quality and data quality assessment in the big data era. Data Sci J. 2015;14:4–29.CrossRef
34.
Zurück zum Zitat Azadmanjir Z, Jazayeri SB, Habibi Arejan R, Ghodsi Z, Sharif-Alhoseini M, Kheiri G, et al. The data set development for the National Spinal Cord Injury Registry of Iran (NSCIR-IR): progress toward improving the quality of care. Spinal Cord Ser Cases. 2020;6(1):17.CrossRefPubMedPubMedCentral Azadmanjir Z, Jazayeri SB, Habibi Arejan R, Ghodsi Z, Sharif-Alhoseini M, Kheiri G, et al. The data set development for the National Spinal Cord Injury Registry of Iran (NSCIR-IR): progress toward improving the quality of care. Spinal Cord Ser Cases. 2020;6(1):17.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Lash TL, Fox MP, Fink AK. Applying quantitative bias analysis to epidemiologic data: Springer; 2009. Lash TL, Fox MP, Fink AK. Applying quantitative bias analysis to epidemiologic data: Springer; 2009.
Metadaten
Titel
Development and evaluation of a customized checklist to assess the quality control of disease registry systems of Tehran, the capital of Iran in 2021
verfasst von
Maryam Barzin
Hamideh Sabbaghi
Sharareh Kamfar
Atena Seifi
Mahmoud Hajipour
Fatemeh Hadavand Siri
Elham Mir-Moeini
Anis Gharajeh
Nasrin Ferdosifard
Mohammadhossein Panahi
Seyed Saeed Hashemi Nazari
Fatemeh Fallah Atatalab
Koorosh Etemad
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
BMC Health Services Research / Ausgabe 1/2023
Elektronische ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-023-09605-2

Weitere Artikel der Ausgabe 1/2023

BMC Health Services Research 1/2023 Zur Ausgabe